RCS - Physiomics PLC - Contract announcement

PhysiomicsAnnouncement

10/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230310:nRSJ5050Sa&default-theme=true

RNS Number : 5050S  Physiomics PLC  10 March 2023

10 March 2023

 

Physiomics plc

("Physiomics") or ("the Company")

 

Contract announcement

 

Physiomics plc (AIM: PYC), the consultancy using mathematical models to
support the development of drug treatment regimens and personalised medicine
solutions, is pleased to announce that it has been awarded a further contract
by existing client Bicycle Therapeutics ("Bicycle").  The project relates to
an undisclosed program and is expected to be completed in the Company's
current financial year.

 

Dr Jim Millen, CEO of Physiomics, commented: "We are delighted that Bicycle
has chosen us to support this new project.  Physiomics has been working with
Bicycle since 2019 and has been involved in various Bicycle programs spanning
discovery through clinical development.  We look forward to working with this
valued client once again."

 

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 100 projects, involving over 40 targets and 70 drugs, and
has worked with clients such as Merck KGaA, Astellas, Merck & Co and
Bicycle Therapeutics.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAVKLFBXXLLBBF